Objective: The objectives of the present study were to demonstrate the influence of neutrophils, platelets, and neutrophil-lymphocyte ratio (NLR) in the ovarian cancer prognosis and to compare these parameters with benign ovarian neoplasms.
INTRODUCTION
Ovarian cancer is currently the leading cause of death among gynecologic cancers. An early diagnosis for this cancer is difficult because patients present with nonspecific symptoms in the early stages of disease. [1] Consequently, a diagnosis of Stage III or IV ovarian cancer is usually made. Despite improvements in surgical techniques and the advent of new chemotherapy regimens, the rates of survival have remained relatively unchanged. [2] Recent studies have demonstrated the importance of a patient's inflammatory response in combination with genetic and environmental predisposition for carcinogenesis and cancer progression. There are multiple types of cells in tumors that can contribute to tumor development. [3, 4] In particular, endothelial cells, fibroblasts, and inflammatory cells have key roles. [5] Among inflammatory cells, neutrophils mediate a negative effect by p ro m o t i n g a n g i o g e n e s i s a n d i m m u n e suppression, as well as the migration, invasion, and metastasis of tumors. [6] Thus, the presence of tumor-infiltrating neutrophils, neutrophilia, and a high neutrophil/lymphocyte ratio (NLR) in the blood have been associated with poor clinical prognosis in various human cancers, including ovarian cancer. [7, 8] Other parameter associated with tumor prognosis is platelet count. Preoperative thrombocytosis is a frequent finding in cases of ovarian carcinoma, and an association between advanced cancer stage and high-grade carcinomas has been identified, thereby suggesting that platelets may
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This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms. play a role in tumor growth and progression. [9, 10] A shorter disease-free survival period has also been observed in patients with epithelial ovarian cancer and preoperative thrombocytosis. [9] The identification of new markers and methods for an early diagnosis of ovarian cancer, as well as new prognostic factors, are needed. Therefore, the aims of the present study were to assess and compare the platelet count and NLR in the peripheral blood of patients with benign versus malignant ovarian tumors before surgery, identify possible associations between NLR and preoperative platelet count with clinical, laboratory, and pathological prognostic factors in cases of malignant ovarian cancer, and verify whether chemotherapy-induced neutropenia during treatment is related to disease-free survival.
MATERIALS AND METHODS
This retrospective study was approved by the Research Ethics Committee of the University. Patients who were treated at the Pelvic Mass Clinic and underwent surgery for an ovarian cyst were evaluated. Each cyst received a confirmed pathological diagnosis of malignant (n = 72) or benign (n = 213). The criteria for surgical treatment were anechoic cysts with a maximum diameter of <7 cm, with persistence of alteration for more than 6 months and normal tumor markers; altered tumor markers; anechoic cysts with a maximum diameter ≥7 cm; ovarian masses with solid contents, presence of intracystic vegetation, thick septa, 2 or more fine septa; bilaterality; presence of ascites; and Doppler color with resistance index ≤0.4. [11, 12] Laparotomy was the approach of choice except for anechoic and small cysts. Patients who needed chemotherapy used platinum-based regimens.
The inclusion criterion was the histological diagnosis of ovarian neoplasia. Exclusion criteria were torsion of the adnexal pedicle, secondary malignant ovarian neoplasia (metastasis), previous antineoplastic treatment; immunosuppressive diseases; and relapse.
Regarding histological grade, malignant neoplasms were classified as well differentiated (Grade 1), moderately differentiated (Grade 2), and poorly differentiated (Grade 3). Well-differentiated tumors and Stages I and II (FIGO) were considered tumors of better prognosis than moderate and poorly differentiated tumors and Stages III and IV.
For each patient, age, parity, histologic type, tumor stage, type of surgery performed, chemotherapy, disease-free survival, and serum levels of tumor markers, neutrophils, lymphocytes, and platelets were recorded. NLR was evaluated during chemotherapy and was also recorded.
Data were analyzed with GraphPad Prism software 6 (La Jolla, CA, USA) and SPSS software (Version 22.0. Armonk, NY: IBM Corp). Mann-Whitney test was used to compare benign and malignant groups, and Chi-square test was used to assess prognostic factors. Subsequently, a multivariate analysis was performed (multiple linear regression). A P < 0.05 was established as the significance level.
RESULTS
Platelet counts, absolute number of neutrophils, and NLR were higher in malignant ovarian tumors group compared with benign ovarian tumors group (P = 0.0132, P = 0.0208, and P < 0.0001, respectively). In contrast, absolute lymphocyte counts were lower in the malignant tumor patients compared with the benign tumor patients (P < 0.0001) [ Table 1 ].
A NLR <3 was associated with Stages I and II ovarian tumors (P = 0.0053), thereby suggesting a better prognosis. However, there were no statistically significant associations identified between NLR and tumor grade, histological type, or lymph node status. Regarding histological grade, platelet serum levels <350,000/mm 3 were found to be related to histological Grade 1 (P = 0.02). An analysis of the absolute number of neutrophils present in patients undergoing chemotherapy demonstrated that the incidence of neutropenia during treatment was related to disease-free survival. In particular, patients with a disease-free survival period longer than 24 months more frequently developed neutropenia (a neutrophil count <1200/mm 3 ) during chemotherapy (P = 0.0482) [ Figure 1 ].
Subsequently, multivariate analysis (multiple linear regression) was performed. Platelets, NLR, and serum levels of CA15.3 were considered independent variables related to tumor staging (P = 0.028, P = 0.028, and P = 0.035, respectively). Regarding the histological grade, no significant association was found [ Table 2 ].
DISCUSSION
An inflammatory response can lead to an increase in neutrophil levels and a reduction in lymphocyte levels. [13] For ovarian tumors, platelet count may be higher in malignant tumors compared with benign tumors. [14] [15] [16] In a study that evaluated the association between preoperative NLR and histopathologically diagnosed adnexal tumors, higher NLR values predicted ovarian cancer with a cutoff value of 3.35 (sensitivity 55% and specificity 81%). [17] The NLR, platelet-lymphocyte ratio, and neutrophil, CA-125, and platelet values were higher in the malignant neoplasms compared with the benign tumors, whereas lymphocyte values were lower in cases of ovarian cancer. [18] One study demonstrated that the association of thrombocytosis with CA-125 levels improves specificity and positive predictive value in the diagnosis of malignant adnexal tumors. [16] In the present study, NLR and absolute neutrophil counts were higher, while the absolute number of lymphocytes was lower, in the cases of ovarian cancer that were examined. There is visible strong need of more numerous study groups for analyzes the role of NLR in the differentiation between benign and malignant neoplasms.
Blood count parameters have been linked to the prognosis for both malignant and borderline ovarian tumors. [19] [20] [21] [22] [23] For tumor-infiltrating neutrophils, elevated blood neutrophils and a high NLR have been associated with a worse prognosis for several types of malignancies. In addition, less effective therapeutic results have been achieved when neutrophil counts are high. [7] High preoperative and postoperative NLRs have also been associated with advanced stage tumors and suboptimal surgeries, respectively. [24] For patients with ovarian cancer, high preoperative values of NRL have been associated with a worse response to platinum-based, first-line chemotherapy, and poor clinical outcome. [25] NRL has also been related to advanced FIGO stage, higher CA-125 serum levels, more extensive ascites, less chemotherapeutic response, [26] and shorter overall survival and disease-free survival. [8] CA-125 positively correlates with neutrophil count and inversely correlates with lymphocyte count, thereby suggesting that tumors secrete CA-125 and neutrophilic growth factors. [27] These data are in agreement with our study, in which NLR <3 was associated with Stages I and II ovarian tumors. Multivariate analysis demonstrated that NLR is directly related to staging.
One of the parameters associated with tumor prognosis is platelet count and preoperative thrombocytosis frequently presents in cases of ovarian carcinoma. For patients with advanced epithelial ovarian cancer, an association between advanced tumor stage and poor prognostic factors of survival have been observed. [9, 15, 28] A high platelet count at the time of debulking surgery has also been associated with suboptimal resection and a shorter overall survival period. [29] This can be explained by the direct proliferative effect of platelets on cancer cells that have been observed both in vivo and in vitro, thereby suggesting that patients with ovarian cancer and thrombocytosis have high rates of tumor proliferation compared with patients with normal platelet counts. [30] In the present study, circulating platelet levels <3,50,000 platelets/mm 3 were associated with well-differentiated tumors, and this would suggest a better prognosis. In multivariate analysis, absolute platelet value was directly related to staging.
Conventionally, neutropenia is considered a side effect of chemotherapy that should be avoided. Moreover, chemotherapy-induced neutropenia has been associated with prognosis in various types of cancer. [31] [32] [33] [34] [35] In a meta-analysis, chemotherapy-induced neutropenia or leukopenia was found to be related to improved survival in patients with advanced cancer or hematological malignancies. [36] However, in another study, no relationship between chemotherapy-induced neutropenia and prognosis in ovarian cancer was observed. [37] In the present study, patients with a disease-free survival period longer than 24 months more frequently developed neutropenia during chemotherapy.
The discovery of new prognostic factors in ovarian cancer may lead to better treatment. Thus, more aggressive adjuvant treatments may be performed in patients with worse prognostic factors. In addition, the blood count is an inexpensive and affordable test.
The main limitation of the study is the small amount of patients. Further studies with a larger sample are needed to better elucidate the role of platelets and NLR in ovarian cancer. Our data demonstrate that these blood count parameters may represent potential prognostic factors in ovarian cancer, and they may also serve as therapeutic targets in the future treatment strategies.
